We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Changes from induction to week 24 in bowel wall ...

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

Dong-A-ST's Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, has won the Food and Drug Administration’s approval. “This FDA approval indicates ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara. But with biosimilar versions of the autoimmune blockbuster quickly ...

For the millions of Americans living with chronic inflammatory conditions, which can be painful, and also can have a significant impact on quality of life, emotional well-being, and self-image, ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The FDA recently approved STELARA, a prescription medication for adults suffering from Crohn’s disease. Here’s what you need to know: 1. STELARA is manufactured by Janssen Biotech. 2. This treatment ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline ...